Notice: A non well formed numeric value encountered in /home/lookformedical/www/web.php on line 172

Notice: A non well formed numeric value encountered in /home/lookformedical/www/web.php on line 172
*  Effect of Interleukin-2 on HIV Treatment Interruption - Full Text View - ClinicalTrials.gov
Drug Administration Schedule. CD4 Lymphocyte Count. Anti-HIV Agents. Tetanus Toxoid. Aldesleukin. Diphtheria Toxoid. ... Cancer requiring anti-cancer drugs. *Thyroid problems. If the condition has been controlled by drugs for at least 3 months ... Physiological Effects of Drugs. Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. ... Aldesleukin. Interleukin-2. Antineoplastic Agents. Analgesics, Non-Narcotic. Analgesics. Sensory System Agents. Peripheral ...
  https://clinicaltrials.gov/ct2/show/study/NCT00015704?view=record
*  Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients - Full Text View - ClinicalTrials.gov
Drug Therapy, Combination. Drug Administration Schedule. Viremia. T-Lymphocytes, Cytotoxic. Anti-HIV Agents. Treatment ... Drug: Aldesleukin Subcutaneous injection of IL-2 in the amount of 2.0 X 10^6 mIU per day for the entire duration of therapy ... Drug: HAART Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is ... Drug: HAART Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is ...
  https://www.clinicaltrials.gov/ct2/show/NCT00001131
*  Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy - Full Text View -...
Drug Administration Schedule. CD4 Lymphocyte Count. Anti-HIV Agents. Viral Load. Treatment Interruption. Treatment Experienced ... Aldesleukin. Interleukin-2. Antineoplastic Agents. Analgesics, Non-Narcotic. Analgesics. Sensory System Agents. Peripheral ... Anti-HIV drug regimen of at least 3 anti-HIV drugs for at least 6 months immediately prior to study entry ... Current use of experimental anti-HIV drugs other than FDA sanctioned investigational drugs ...
  https://clinicaltrials.gov/show/NCT00038259?order=198
*  A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in...
Drug: Indinavir sulfate Drug: Lamivudine Drug: Stavudine Drug: Zidovudine Drug: Didanosine Drug: Aldesleukin Phase 2 ... Drug Administration Schedule. CD4 Lymphocyte Count. Quality of Life. Anti-HIV Agents. ... Patients must be able to initiate one of the following nucleoside analogue regimens of which at least one of the drugs must be ... Ability to initiate one of the following nucleoside analogue regimens of which one of the drugs must be new to the patient: ...
  https://clinicaltrials.gov/show/NCT00000870?order=274
*  A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3...
For this study, a course is defined as eight calendar weeks, including the five-day period of sc rIL-2 administration. ... Drug: Aldesleukin Phase 3 Detailed Description:. There is substantial evidence that rIL-2 increases CD4+ cell count. Whether or ... Dose-Response Relationship, Drug. Adolescent Behavior. CD4 Lymphocyte Count. RNA, Viral. Quality of Life. Anti-HIV Agents. ... The drug rIL-2 has been shown to increase CD4 cell counts, which help the body fight off HIV. ...
  https://clinicaltrials.gov/show/NCT00000949?order=610
*  A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3...
For this study, a course is defined as eight calendar weeks, including the five-day period of sc rIL-2 administration. ... Drug: Aldesleukin. Study Arms Not Provided. Publications * Abrams DI, Bebchuk JD, Denning ET, Davey RT, Fox L, Lane HC, Sampson ... The drug rIL-2 has been shown to increase CD4 cell counts, which help the body fight off HIV. ... of this study is to examine how rIL-2 affects HIV-positive patients with CD4 counts over 300 cells/mm3 who are on anti-HIV drug ...
  https://clinicaltrials.gov/ct2/show/record/NCT00000949?view=results
*  Drug Summary
... dosing and administering information to help phsyicans more efficiently and accurately prescribe in their practice PDR's drug ... PDR Drug Summaries are concise point-of-care prescribing, ... Prior to the administration of the vaccine, the health care ... Aldesleukin, IL-2: (Severe) Aldesleukin, IL-2 is associated with impaired neutrophil function. Live virus vaccines should ... The Advisory Committee on Immunization Practiced (ACIP) recommends a 2-dose vaccine schedule in childhood, with the first dose ...
  http://www.pdr.net/drug-summary/Varivax-varicella-virus-vaccine-live-397
*  YF-Vax (yellow fever vaccine) dose, indications, adverse effects, interactions... from PDR.net
... dosing and administering information to help phsyicans more efficiently and accurately prescribe in their practice PDR's drug ... PDR Drug Summaries are concise point-of-care prescribing, ... Prior to the administration of the vaccine, the health care ... Aldesleukin, IL-2: (Severe) Aldesleukin, IL-2 is associated with impaired neutrophil function. Live virus vaccines should ... Canakinumab: (Major) Do not administer live vaccines to a patient who is receiving canakinumab; other vaccination schedules ...
  http://www.pdr.net/drug-summary/yf-vax?druglabelid=1721
*  National Drug Schedules | NAPRA
when recommended for administration by intravenous injection. I. DEC / 13. Acetaminophen in sustained release formulations. up ... AldesleukinPDL. I. DEC / 13. Alectinib or its saltsPDL. I. NOV / 16. ... National Drug Schedules Expand/Collapse National Drug Schedules * Drug Scheduling in Canada ... National Drug Schedules Expand/Collapse National Drug Schedules * Drug Scheduling in Canada ...
  http://napra.ca/national-drug-schedules?letter=a&page=1
*  IL-2 - Drug Information - Chemocare
Aldesleukin) biologic response modifier side effects, how it's given, how it works, precautions and self care tips for ... Proleukin® is the trade name for the generic drug name Aldesleukin. IL-2 and Interleukin-2 are other names for Aldesleukin. In ... The U.S. Food and Drug Administration approved it in its synthetic form for treatment against cancer in 1992. ... Sustained fever (fever lasting/occurring beyond the expected timeframe for dose and schedule). ...
  http://chemocare.com/chemotherapy/drug-info/il-2.aspx
*  Interleukin-2 - UNM Comprehensive Cancer Center
For which conditions is this drug approved?. Aldesleukin is currently FDA approved for the treatment of metastatic melanoma and ... A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects ... During administration, patients receiving aldesleukin may experience serious side effects attributed to a condition called ... Therefore, it is advised that patients treated with higher doses of aldesleukin be closely supervised during administration, ...
  http://cancer.unm.edu/2009/12/29/interleukin-2-2/
*  Nystatin and Triamcinolone (Professional Patient Advice) - Drugs.com
Drug Interactions. Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination ... Administration. External use only; do not use on open or weeping wounds; do not use with occlusive dressings. ... CSA Schedule* Not a controlled drug. Approval History Drug history at FDA ... Drugs.com Mobile Apps. The easiest way to lookup drug information, identify pills, check interactions and set up your own ...
  https://www.drugs.com/ppa/nystatin-and-triamcinolone.html
*  Fluticasone (Topical) (Professional Patient Advice) - Drugs.com
Drug Interactions. Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination ... Administration. Topical: Apply sparingly in a thin film. Rub in lightly. Avoid contact with eyes; generally not for routine use ... CSA Schedule Not a controlled drug. Approval History Drug history at FDA ... Drugs.com Mobile Apps. The easiest way to lookup drug information, identify pills, check interactions and set up your own ...
  https://www.drugs.com/ppa/fluticasone-topical.html
*  US Patent # 9,586,948. Inhibitors of IRAK4 activity - Patents.com
... dosing schedule and route of administration will be determined based upon the specific second therapeutic agent that is being ... The tablets may be uncoated or they may be coated by known techniques to mask the unpleasant taste of the drug or delay ... In one embodiment, the anti-cancer agent is selected from the group consisting of abarelix (Plenaxis depot.RTM.); aldesleukin ( ... the administration for a compound of the instant invention is oral administration. In another embodiment, the administration ...
  http://patents.com/us-9586948.html
*  Budesonide (Topical) (Professional Patient Advice) - Drugs.com
Drug Interactions. Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination ... Administration. Rectal: Rectal foam: For rectal use only; not for oral use. Wash hands before and after use. Prior to use, ... CSA Schedule* Not a controlled drug. Approval History Drug history at FDA ... Drugs.com Mobile Apps. The easiest way to lookup drug information, identify pills, check interactions and set up your own ...
  https://www.drugs.com/ppa/budesonide-topical.html
*  US Patent # 9,393,258. Methods and compositions for the inhibition of gene expression - Patents.com
Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. The administering ... For example, the U.S. Food and Drug Administration maintains a formulary of oncolytic agents approved for use in the United ... TABLE-US-00002 TABLE 3 Aldesleukin Proleukin Chiron Corp., (des-alanyl-1, serine-125 human Emeryville, CA interleukin-2) ... C. Drug Screening In other embodiments, the methods and compositions of the present invention are used in drug screening ...
  http://patents.com/us-9393258.html
*  Sunitinib - Wikipedia
US Food and Drug Administration (2006). "FDA approves new treatment for gastrointestinal and kidney cancer". Hartmann JT, Kanz ... If this is done at the end of a calendar year, it has to be paid again at the beginning of the next calendar year, which may be ... and aldesleukin. RCC is generally resistant to chemotherapy or radiation. Prior to RTKs, metastatic disease could only be ... BMJ 31-Jan-2009 "NICE and the challenge of cancer drugs" p271 BBC news - Aug 2008 - 'We'll sell our house for this drug' Daily ...
  https://en.wikipedia.org/wiki/Sunitinib
*  Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the...
High-dose recombinant interleukin-2 (rIL-2, aldesleukin, Proleukin) was approved by the U.S. Food and Drug Administration in ... Following 9 days of rest, the schedule was repeated for up to 14 doses, for a maximum of 28 doses per course, as tolerated. ... Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the ... Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the ...
  http://clincancerres.aacrjournals.org/content/17/23/7440.long
*  Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD - Full Text View - ClinicalTrials.gov
Experimental: IL2 Administration SCHEDULE OF IL-2 ADMINISTRATION: Patients will receive a fixed dose (1x10e5 units/m2/dose) of ... A drug known as IL-2 (Proleukin) has been shown to increase the number of regulatory T cells in patients following stem cell ... IL2 Administration:. Patients will be given a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three ... EXCLUSION CRITERIA AT TIME OF IL-2 ADMINISTRATION:. Patients will be ineligible to receive IL-2 injections if any of the ...
  https://clinicaltrials.gov/ct2/show/NCT00539695
*  Hydrocortisone (Topical) (Professional Patient Advice) - Drugs.com
Drug Interactions. Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination ... Administration. Topical cream, lotion, ointment: Apply a thin film to clean, dry skin and rub in gently. Shake lotion well ... CSA Schedule* Not a controlled drug. Approval History Drug history at FDA ... Drugs.com Mobile Apps. The easiest way to lookup drug information, identify pills, check interactions and set up your own ...
  https://www.drugs.com/ppa/hydrocortisone-topical.html
*  Mometasone (Oral Inhalation) (Professional Patient Advice) - Drugs.com
Drug Interactions. Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination ... Administration. Asmanex HFA: Shake well prior to each inhalation. Administer as 2 inhalations twice daily (morning and evening ... CSA Schedule Not a controlled drug. Approval History Drug history at FDA ... Concurrent drug therapy issues:. • Drug-drug interactions: Potentially significant interactions may exist, requiring dose or ...
  https://www.drugs.com/ppa/mometasone-oral-inhalation.html
*  US Patent # 9,987,258. Histone deacetylase as a modulator of PDL1 expression and activity - Patents.com
Administration of the disclosed compounds or compositions can be a single administration, or at continuous or distinct ... Numerous anti-cancer drugs are available for combination with the present method and compositions. The following is a non- ... When tumors became palpable, treatment with 15 mg/kg LBH589 via IP injection began on a Mon, Wed, Fri schedule. After one week ... Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase ...
  http://patents.com/us-9987258.html
*  Prometheus launches PROCLIVITY 02, a phase IV multi-center study | Nestlé Health Science
Proleukin administration has been associated with capillary leak syndrome (CLS), which is characterized by a loss of vascular ... Finally, the fraction of patients in each arm who receive , 50% of the cycles of both drugs will be compared to each other. ... or visit www.clinicaltrials.gov (enter aldesleukin or PROCLIVITY in the "search" box on the top right). The PROCLIVITY clinical ... Following 9 days of rest, the schedule is repeated for another 14 doses, for a maximum of 28 doses per course, as tolerated. ...
  https://www.nestlehealthscience.com/newsroom/press-releases/Prometheus-Laboratories-Launches-Next-Clinical-Trial
*  Interferon Alfacon-1 (Professional Patient Advice) - Drugs.com
Drug Interactions. Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of ... Allow to reach room temperature just prior to administration.. Storage. Store in refrigerator 2°C to 8°C (36°F to 46°F); do not ... Drugs.com Mobile Apps. The easiest way to lookup drug information, identify pills, check interactions and set up your own ... Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and ...
  https://www.drugs.com/ppa/interferon-alfacon-1.html
*  Drug Summary
... dosing and administering information to help phsyicans more efficiently and accurately prescribe in their practice PDR's drug ... PDR Drug Summaries are concise point-of-care prescribing, ... DRUG INTERACTIONS. Aldesleukin, IL-2: (Moderate) The safety and ... Following IV administration, mechlorethamine is rapidly transformed to its active form; unchanged drug is undetectable in the ... If the reduced frequency schedule is tolerated for 1 week, increase the application frequency to once every other day for 1 ...
  http://www.pdr.net/drug-summary/Valchlor-mechlorethamine-3361